You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

AMLODIPINE AND OLMESARTAN MEDOXOMIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Amlodipine And Olmesartan Medoxomil patents expire, and what generic alternatives are available?

Amlodipine And Olmesartan Medoxomil is a drug marketed by Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Micro Labs, Sciegen Pharms Inc, Teva Pharms Usa, Torrent, and Zydus Pharms. and is included in thirteen NDAs.

The generic ingredient in AMLODIPINE AND OLMESARTAN MEDOXOMIL is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AMLODIPINE AND OLMESARTAN MEDOXOMIL?
  • What are the global sales for AMLODIPINE AND OLMESARTAN MEDOXOMIL?
  • What is Average Wholesale Price for AMLODIPINE AND OLMESARTAN MEDOXOMIL?
Summary for AMLODIPINE AND OLMESARTAN MEDOXOMIL
US Patents:0
Applicants:13
NDAs:13
Finished Product Suppliers / Packagers: 15
Clinical Trials: 14
What excipients (inactive ingredients) are in AMLODIPINE AND OLMESARTAN MEDOXOMIL?AMLODIPINE AND OLMESARTAN MEDOXOMIL excipients list
DailyMed Link:AMLODIPINE AND OLMESARTAN MEDOXOMIL at DailyMed
Drug patent expirations by year for AMLODIPINE AND OLMESARTAN MEDOXOMIL
Recent Clinical Trials for AMLODIPINE AND OLMESARTAN MEDOXOMIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daiichi Sankyo Korea Co., Ltd.Phase 3
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo CompanyPhase 3
Torrent Pharmaceuticals LimitedPhase 1

See all AMLODIPINE AND OLMESARTAN MEDOXOMIL clinical trials

US Patents and Regulatory Information for AMLODIPINE AND OLMESARTAN MEDOXOMIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa AMLODIPINE AND OLMESARTAN MEDOXOMIL amlodipine besylate; olmesartan medoxomil TABLET;ORAL 091154-001 Oct 26, 2016 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Macleods Pharms Ltd AMLODIPINE AND OLMESARTAN MEDOXOMIL amlodipine besylate; olmesartan medoxomil TABLET;ORAL 206884-004 Oct 26, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms AMLODIPINE AND OLMESARTAN MEDOXOMIL amlodipine besylate; olmesartan medoxomil TABLET;ORAL 207771-001 Sep 22, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Torrent AMLODIPINE AND OLMESARTAN MEDOXOMIL amlodipine besylate; olmesartan medoxomil TABLET;ORAL 202933-001 Nov 25, 2016 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.